Bagsværd, Denmark, 4 February 2020 – On 5 November 2019, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 1 February 2019.
Under the programme, initiated 5 November 2019, Novo Nordisk has repurchased B shares for an amount up to DKK 2.1 billion in the period from 6 November 2019 to 3 February 2020. The programme is now concluded.
Since the announcement as of 27 January 2020, the following transactions have been made:
Number of B shares | Average purchase price | Transaction value, DKK | |
Accumulated, last announcement | 4,832,350 | 1,878,714,254 | |
27 January 2020 | 90,000 | 409.39 | 36,844,685 |
28 January 2020 | 90,000 | 406.33 | 36,570,124 |
29 January 2020 | 90,000 | 413.00 | 37,170,423 |
30 January 2020 | 90,000 | 413.32 | 37,198,355 |
31 January 2020 | 97,000 | 414.85 | 40,240,402 |
3 February 2020 | 96,232 | 411.39 | 39,588,765 |
Accumulated under the programme | 5,385,582 | 2,106,327,008 |
The details for each transaction made under the share repurchase programme are published on novonordisk.com.
With the transactions stated above, Novo Nordisk owns a total of 50,320,781 B shares of DKK 0.20, corresponding to 2.1% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,400,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 1 February 2019. As of 3 February 2020, Novo Nordisk has since 1 February 2019 repurchased a total of 43,209,505 B shares at an average share price of DKK 347.15 per B share equal to a transaction value of DKK 14,999,999,626.
Further information
Media: | ||
Anne Margrethe Hauge | +45 4442 3450 | amhg@novonordisk.com |
Ken Inchausti (US) | +1 609 240 9429 | kiau@novonordisk.com |
Investors: | ||
Peter Hugreffe Ankersen | +45 3075 9085 | phak@novonordisk.com |
Valdemar Borum Svarrer | +45 3079 0301 | jvls@novonordisk.com |
Ann Søndermølle Rendbæk | +45 3075 2253 | arnd@novonordisk.com |
Mark Joseph Root | +45 3079 4211 | mjhr@novonordisk.com |
Kristoffer Due Berg (US) | +1 609 235 2989 | krdb@novonordisk.com |
Company announcement No 6 / 2020
Attachment